These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27432932)

  • 61. Review of mortality results in randomised trials in early breast cancer.
    Lancet; 1984 Nov; 2(8413):1205. PubMed ID: 6150246
    [No Abstract]   [Full Text] [Related]  

  • 62. [Novel target therapies used in breast cancer management].
    Semiglazova TIu; Semiglazov VV; Filatova LV; Gershanovich ML; Chudenko VA; Latipova DKh; Luk'ianchikova VS; Dashian GA; Paltuev RM
    Vopr Onkol; 2011; 57(5):592-600. PubMed ID: 22238928
    [No Abstract]   [Full Text] [Related]  

  • 63. Translating neoadjuvant therapy into survival benefits: one size does not fit all.
    De Mattos-Arruda L; Shen R; Reis-Filho JS; Cortés J
    Nat Rev Clin Oncol; 2016 Sep; 13(9):566-79. PubMed ID: 27000962
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Methodological features of assessing the effectiveness of adjuvant therapy in clinical trials].
    Dvoĭrin VV
    Vopr Onkol; 1986; 32(6):18-22. PubMed ID: 3523991
    [No Abstract]   [Full Text] [Related]  

  • 65. Clinical and molecular aspects of breast cancer: Targets and therapies.
    Godone RLN; Leitão GM; Araújo NB; Castelletti CHM; Lima-Filho JL; Martins DBG
    Biomed Pharmacother; 2018 Oct; 106():14-34. PubMed ID: 29945114
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Innovative therapies for metastatic melanoma in elderly patients].
    Du-Thanh A; Lesage C; Ferreira E; Dereure O; Guillot B
    Ann Dermatol Venereol; 2015 Oct; 142(10):549-56. PubMed ID: 25986740
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Targeting HER2 in Advanced Breast Cancer.
    Zhu X; Joy AA
    Methods Mol Biol; 2017; 1652():63-77. PubMed ID: 28791634
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Adjuvant therapy for node-negative breast cancer: a cautious interpretation.
    Henderson IC
    Important Adv Oncol; 1990; ():199-216. PubMed ID: 1691137
    [No Abstract]   [Full Text] [Related]  

  • 69. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review.
    Huillard O; Bakalian S; Levy C; Desjardins L; Lumbroso-Le Rouic L; Pop S; Sablin MP; Le Tourneau C
    Eur J Cancer; 2014 Feb; 50(3):638-48. PubMed ID: 24256808
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Advances in the treatment of advanced oestrogen-receptor-positive breast cancer.
    Turner NC; Neven P; Loibl S; Andre F
    Lancet; 2017 Jun; 389(10087):2403-2414. PubMed ID: 27939057
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval.
    Berry DA; Hudis CA
    JAMA Oncol; 2015 Oct; 1(7):875-6. PubMed ID: 26181139
    [No Abstract]   [Full Text] [Related]  

  • 72. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
    Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
    Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Adjuvant systemic therapy for resectable breast cancer.
    Bonadonna G; Valagussa P
    J Clin Oncol; 1985 Feb; 3(2):259-75. PubMed ID: 3881562
    [No Abstract]   [Full Text] [Related]  

  • 75. Current and emerging first-line systemic therapies in clear cell renal cell carcinoma.
    Rini BI
    Clin Adv Hematol Oncol; 2018 Feb; 16(2):115-117. PubMed ID: 29741511
    [No Abstract]   [Full Text] [Related]  

  • 76. [Modern pharmacological therapy of breast cancer].
    Láng I; Kahán Z; Hitre E; Dank M; Rubovszky G; Horváth Z; Kásler M
    Orv Hetil; 2012 Jan; 153(2):56-65. PubMed ID: 22217685
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Anti-vascular endothelial growth factor therapy in breast cancer.
    Kristensen TB; Knutsson ML; Wehland M; Laursen BE; Grimm D; Warnke E; Magnusson NE
    Int J Mol Sci; 2014 Dec; 15(12):23024-41. PubMed ID: 25514409
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment.
    Gu G; Dustin D; Fuqua SA
    Curr Opin Pharmacol; 2016 Dec; 31():97-103. PubMed ID: 27883943
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Adjuvant radiotherapy trials in breast cancer.
    Stjernswärd J
    Cancer; 1977 Jun; 39(6 Suppl):2846-67. PubMed ID: 326382
    [No Abstract]   [Full Text] [Related]  

  • 80. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.
    Austreid E; Lonning PE; Eikesdal HP
    Expert Opin Pharmacother; 2014 Apr; 15(5):681-700. PubMed ID: 24579888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.